Last reviewed · How we verify
Octadecanoic Acid (stearic acid)
Stearic acid, a marketed compound, operates by binding to the peroxisome proliferator-activated receptor alpha, a critical regulator of lipid metabolism, but lacks a defined primary indication or revenue data. Its key competitive advantage lies in the 2028 expiry of its key composition patent, providing a window of exclusivity before potential generic competition. The primary risk is the presence of multiple off-patent competitors such as choline fenofibrate and clofibrate, which may limit market share and pricing power.
At a glance
| Generic name | stearic acid |
|---|---|
| Drug class | stearic acid |
| Target | Fatty acid-binding protein, adipocyte, Peroxisome proliferator-activated receptor delta, Tyrosine-protein phosphatase non-receptor type 1 |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of L. Reuteri LM1063 on Sleep Health Improvement (NA)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition (PHASE2)
- Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels (NA)
- Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis (PHASE2)
- Phase I Trial of Defactinib and VS-6766. (PHASE1)
- Cabozantinib for Patients With Recurrent or Progressive Meningioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octadecanoic Acid CI brief — competitive landscape report
- Octadecanoic Acid updates RSS · CI watch RSS
- portfolio CI